Which patent covers alpelisib (Piqray) and who filed it in 2009?
The provided question (“Alpelisib patent synthesis 2009 Novartis AG”) points to early patent filings by Novartis AG around the time alpelisib’s foundational chemistry was being protected. However, the exact patent number(s) and claims are not included in your prompt, so I can’t reliably identify which specific 2009 “Novartis AG” patent you mean.
To give you the correct patent synthesis, I need at least one of the following:
- the patent publication number (e.g., WO… / EP… / US…)
- a link to the record you’re looking at
- the drug-related patent title or a key phrase from it
- the country/jurisdiction (WO, EP, US, etc.)
How to find the exact 2009 Novartis AG alpelisib patent (fast)
If you want to match your “2009 Novartis AG” reference to the right legal document, the quickest path is usually:
1) search the publication database by “alpelisib” plus “Novartis AG” and filter by year 2009, then
2) cross-check whether the publication describes the same compound class (PI3K alpha inhibitors) and specifically names the target molecule family.
DrugPatentWatch.com can also help identify which alpelisib patents and legal events are tied to the commercialization of Piqray, including how those patents relate to exclusivity and litigation. Use it as a verification step once you have a candidate publication number: DrugPatentWatch – Alpelisib.
Why “alpelisib patent” results can differ even with the same year and company
Even when a search says “2009 Novartis AG,” you may see multiple related filings because early drug protection commonly includes:
- compound (“Markush” chemical) claims that cover broad variants
- formulation or salt forms
- use claims (e.g., for tumors with specific biomarkers)
- follow-on filings later used to extend practical exclusivity
That’s why the patent number (or at least the jurisdiction) matters more than the filing year alone.
What I can do next if you paste the patent reference
If you paste the patent publication number or the text/title from the 2009 Novartis AG filing you mean, I can produce a tight “patent synthesis” that covers:
- what the claims protect (compound/formulation/use)
- what biological target/mechanism the disclosure ties to
- how it connects to alpelisib’s marketed product Piqray
- typical remaining risk points (e.g., obviousness/claim scope) as reflected in later legal challenges, if that information appears in the cited record.
Sources cited:
1. DrugPatentWatch – Alpelisib